Lantern Pharma reported a GAAP net loss per share of ($0.40) in Q2 2025, and marking an improvement from ($0.46) per share (GAAP) in Q2 2024. As expected for a clinical-stage biotech, no product ...

Allogene Therapeutics' Q2 2025 update highlights a streamlined ALPHA3 trial, promising ALLO-316 data, and financial discipline.

Allogene Therapeutics (NASDAQ:ALLO) reported second-quarter 2025 results on August 13, 2025, highlighting $302.6 million in cash and investments as of the end of Q2 2025 with a projected cash runway ...

Q2 2025 Management View CEO Steven Lo reported that Vaxart received a second stop work order notice on its Phase IIb COVID-19 trial from ATI, the Rapid Response Partnership Vehicles consortium ...

The Oncology Institute (NASDAQ:TOI) reported fiscal second quarter ended June 30, 2025, earnings on August 13, 2025, posting 21.5% year-over-year revenue growth to $119.8 million. Pharmacy revenue ...

Fossil Group(NASDAQ:FOSL) reported results for the second quarter of 2025 on August 13, surpassing expectations with adjusted operating income of $4 million, gross margin of 57.4%, and cost reductions ...

Key Points Earnings per share (Non-GAAP) loss of $0.10 beat expectations by $0.11 and showed a significant improvement from the prior year. Revenue (GAAP) reached $220.4 million, Revenue surpassed the ...

Key Points GAAP revenue declined 30.4% to $19.5 million in Q2 2025 compared to Q2 2024, missing GAAP revenue estimates by $0.9 million. GAAP loss per share widened to $(0.63) in Q2 2025, below ...

Key Points Jasper Therapeutics (NASDAQ:JSPR) reported a GAAP loss per share of $1.74 for Q2 2025. Research and development expenses (GAAP) nearly doubled to $21.2 million in Q2 2025 from $11.3 million ...

Net loss (GAAP) widened year over year for the six months ended Q2 2025, driven by sharply higher research and administrative expenses. Revenue (GAAP) fell 31.0% year-over-year for the six months ...

Revenue-- $564,000 in revenue for fiscal Q2 2025 (period ended June 30, 2025), down from $901,000 in fiscal Q2 2024, reflecting a reduction attributed to lower procedure volumes and a shift in ...

Barfresh Food Group (NASDAQ:BRFH) reported second quarter 2025 results on August 13, 2025, highlighting 11% year-over-year revenue growth to $1.6 million (GAAP) in Q2 FY2025 and milestone achievements ...